Ponatinib-induced neutrophilic panniculitis

May Zhang, Khaled M. Hassan, Amy Musiek, Ilana S. Rosman

Research output: Contribution to journalArticlepeer-review

15 Scopus citations


Ponatinib is a bcr-abl tyrosine-kinase inhibitor (TKI) used to treat resistant and refractory chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia that express bcr-abl. Neutrophilic panniculitis has been described in rare cases of patients on other TKIs in the same class as ponatinib. We present the first case of neutrophilic panniculitis following treatment with ponatinib and summarize the other cases of panniculitis caused by TKIs.

Original languageEnglish
Pages (from-to)597-601
Number of pages5
JournalJournal of cutaneous pathology
Issue number7
StatePublished - Jul 2014


  • chronic myeloid leukemia
  • drug reaction
  • panniculitis
  • ponatinib


Dive into the research topics of 'Ponatinib-induced neutrophilic panniculitis'. Together they form a unique fingerprint.

Cite this